These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2999737)

  • 1. New central dopamine agonists.
    Borsy J
    Pol J Pharmacol Pharm; 1985; 37(3):227-36. PubMed ID: 2999737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
    Fuller RW; Clemens JA; Hynes MD
    J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromocriptine: a rather specific stimulant of dopamine receptors regulating dopamine metabolism.
    Di Chiara G; Vargiu L; Porceddu ML; Gessa GL
    Adv Biochem Psychopharmacol; 1977; 16():443-6. PubMed ID: 578073
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopamine agonist activities of pergolide, its metabolites, and bromocriptine as measured by prolactin inhibition, compulsive turning, and stereotypic behavior.
    Clemens JA; Okimura T; Smalstig EB
    Arzneimittelforschung; 1993 Mar; 43(3):281-6. PubMed ID: 8489554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On some central effects of elymoclavine.
    Roussinov K; Georgiev V; Petkov V; Lazarova M; Petkova B; Shopova S; Markovska V; Getova D; Draganova S
    Acta Physiol Pharmacol Bulg; 1984; 10(4):28-35. PubMed ID: 6442955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anorectic effect of lisuride and other ergot derivatives in the rat.
    Carruba MO; Ricciardi S; Müller EE; Mantegazza P
    Eur J Pharmacol; 1980 Jun; 64(2-3):133-41. PubMed ID: 6105081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic effects on kidney function and responsiveness of aldosterone, plasma renin activity, prolactin, catecholamines, and blood pressure to stimulation in patients with prolactinoma. Comparison of the efficacy of pergolide and bromocriptine therapy.
    Jungmann E; Haak T; Althoff PH; Fassbinder W; Schöffling K
    Arzneimittelforschung; 1988 Feb; 38(2):296-300. PubMed ID: 3285838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mouse locomotor activity: an in vivo test for dopamine autoreceptor activation.
    Martin GE; Bendesky RJ
    J Pharmacol Exp Ther; 1984 Jun; 229(3):706-11. PubMed ID: 6144790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine agonists in the treatment of hyperprolactinemia. Comparison between bromocriptine and lisuride.
    Stracke H; Heinlein W; Horowski R; Schatz H
    Arzneimittelforschung; 1986 Dec; 36(12):1834-6. PubMed ID: 3566845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of mesulergine on prolactin secretion and anterior pituitary cells morphology in diethylstilboestrol-treated female Wistar rats.
    Pisarek H; Stepien H
    Histol Histopathol; 1992 Jan; 7(1):111-7. PubMed ID: 1576426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central monoamine synapses as sites of action for ergot drugs.
    Fuxe K; Ogren SO; Agnati LF; Andersson K; Hall H; Köhler C; Fredholm B
    Adv Biochem Psychopharmacol; 1980; 23():41-62. PubMed ID: 6104914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of AT II on the exploratory behaviour of rats. Interactions with elymoclavine and bromocryptine.
    Petkova B; Georgiev V; Kambourova T
    Acta Physiol Pharmacol Bulg; 1991; 17(2-3):84-90. PubMed ID: 1819920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agonism at 5-HT2B receptors is not a class effect of the ergolines.
    Jähnichen S; Horowski R; Pertz HH
    Eur J Pharmacol; 2005 Apr; 513(3):225-8. PubMed ID: 15862804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre- and postsynaptic action of bromocriptine: its pharmacological effects on shcizophrenia and neurological diseases.
    Trabucchi M; Andreoli VM; Frattola L; Spano PF
    Adv Biochem Psychopharmacol; 1977; 16():661-5. PubMed ID: 196497
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacological and biochemical evidence for the dopamine agonistic effect of bromocriptine.
    Fuxe K; Fredholm BB; Ogren SO; Agnati LF; Hökfelt T; Gustafsson JA
    Acta Endocrinol Suppl (Copenh); 1978; 216():27-56. PubMed ID: 347864
    [No Abstract]   [Full Text] [Related]  

  • 16. Altered behavioral response to a D2 agonist, LY141865, in spontaneously hypertensive rats exhibiting biochemical and endocrine responses similar to those in normotensive rats.
    Fuller RW; Hemrick-Luecke SK; Wong DT; Pearson D; Threlkeld PG; Hynes MD
    J Pharmacol Exp Ther; 1983 Nov; 227(2):354-9. PubMed ID: 6138425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pergolide, a potent long-acting dopamine-receptor agonist.
    Lemberger L; Crabtree R; Callaghan JT
    Clin Pharmacol Ther; 1980 May; 27(5):642-51. PubMed ID: 7189453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of GYKI-32 887 on dopamine (D2) and serotonin (5-HT1 and 5-HT2) receptors.
    Berzétei IP; Bagdy E; Hardy M; Borsy J
    Pol J Pharmacol Pharm; 1985; 37(3):237-42. PubMed ID: 4070077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine analog-induced hyperglycemia in rats: involvement of the adrenal medulla and the endocrine pancreas.
    Arnerić SP; Chow SA; Long JP; Fischer LJ
    J Pharmacol Exp Ther; 1984 Mar; 228(3):551-9. PubMed ID: 6142939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some aspects of the dopaminergic action of ergot derivatives and their role in the treatment of migraine.
    Horowski R
    Adv Neurol; 1982; 33():325-34. PubMed ID: 7055013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.